JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, A. F.
Right arrow Articles by Speck, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, A. F.
Right arrow Articles by Speck, N. A.

 Previous Article  |  Next Article 

Journal of Virology, July 1999, p. 5535-5547, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Core-Binding Factor Influences the Disease Specificity of Moloney Murine Leukemia Virus

Amy F. Lewis,1 Terryl Stacy,1 William R. Green,2 Lekidelu Taddesse-Heath,3 Janet W. Hartley,3 and Nancy A. Speck1,*

Department of Biochemistry1 and Department of Microbiology,2 Dartmouth Medical School, Hanover, New Hampshire 03755, and Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Disease, Bethesda, Maryland 202053

Received 21 December 1998/Accepted 26 March 1999


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The core site in the Moloney murine leukemia virus (Moloney MLV) enhancer was previously shown to be an important determinant of the T-cell disease specificity of the virus. Mutation of the core site resulted in a significant shift in disease specificity of the Moloney virus from T-cell leukemia to erythroleukemia. We and others have since determined that a protein that binds the core site, one of the core-binding factors (CBF) is highly expressed in thymus and is essential for hematopoiesis. Here we test the hypothesis that CBF plays a critical role in mediating pathogenesis of Moloney MLV in vivo. We measured the affinity of CBF for most core sites found in MLV enhancers, introduced sites with different affinities for CBF into the Moloney MLV genome, and determined the effects of these sites on viral pathogenesis. We found a correlation between CBF affinity and the latent period of disease onset, in that Moloney MLVs with high-affinity CBF binding sites induced leukemia following a shorter latent period than viruses with lower-affinity sites. The T-cell disease specificity of Moloney MLV also appeared to correlate with the affinity of CBF for its binding site. The data support a role for CBF in determining the pathogenic properties of Moloney MLV.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Murine leukemia viruses (MLVs) are replication-competent retroviruses, some of which induce leukemias and lymphomas when injected into newborn mice. Both viral and host genetic factors influence the leukemogenicity of MLVs and their disease specificities. One determinant of MLV pathogenesis is the viral transcriptional enhancer. Enhancers can influence the tissue tropism of an MLV, the rate of disease onset, and disease specificity. For example, the SL3-3 MLV, a thymotropic, highly leukemogenic virus, has a potent transcriptional enhancer that significantly influences pathogenesis by this virus. Replacement of the SL3-3 enhancer (U3 region) with that from the weakly leukemogenic Akv virus converts SL3-3 MLV into an essentially nonpathogenic virus (36). Another well-studied example is the enhancer from the Moloney MLV, which determines the selectivity of the Moloney virus for inducing T-cell lymphomas. Substitution of the Moloney virus enhancer with that from the erythroleukemogenic Friend MLV switches the disease specificity of Moloney MLV from T-cell lymphoma to erythroleukemia (9, 10, 22, 31, 38).

An abundance of transcription factor binding sites have been found in MLV enhancers, several of which influence MLV pathogenesis. One site that has received considerable attention is the so-called core site, which was shown to contribute to the pathogenic properties of both the Moloney and SL3-3 MLVs. Mutation of the core site in Moloney MLV significantly altered the disease specificity of Moloney MLV from T-cell lymphoma to erythroleukemia (70). In SL3-3 MLV, core site mutations had different effects, depending upon the particular base pair change that was introduced and the number of core sites mutated. Some mutations increased the latent period of disease onset by SL3-3, while others almost completely attenuated pathogenesis by the virus (1, 27, 47). SL3-3 MLV enhancers containing core site mutations often accumulated secondary mutations in vivo that restored some amount of transcriptional activity to the enhancer and pathogenic potential to the virus (17, 18, 47).

We and others identified and purified a protein that binds the SL3-3 and Moloney MLV core sites and named it CBF (for core-binding factor) (33, 40, 69, 78, 82). We purified CBF from calf thymus based on its ability to bind the wild-type Moloney MLV core site but not the mutated core site that shifted disease specificity of Moloney MLV to erythroleukemia (70, 82). CBF was independently purified based on its binding to the polyomavirus enhancer and is also known as the polyomavirus enhancer binding protein 2 (PEBP2) (33).

Numerous studies have underscored the importance of CBF in hematopoiesis. CBF is a heterodimer consisting of a DNA-binding subunit called CBFalpha and a non-DNA-binding subunit, CBFbeta (33, 54, 55, 83). Three related genes encode CBFalpha subunits (Cbfa1, Cbfa2, and Cbfa3), and one gene encodes the common CBFbeta subunit (Cbfb) (2, 3, 37, 39, 46, 54, 55, 83). Homozygous disruption of two of the CBF genes in mice, Cbfa2 and Cbfb, blocks fetal liver hematopoiesis (48, 56, 64, 80, 81). All definitive hematopoietic lineages are affected by the Cbfa2 and Cbfb mutations, suggesting that Cbfa2 and Cbfb are required at the level of the pluripotent hematopoietic stem cell. In addition, mutations in the human Cbfa2 and Cbfb homologues (CBFA2 [also known as AML1] and CBFB) are associated with leukemias in humans. The CBFA2 gene is the target of the t(8;21)(q22;q22) associated with 15% of de novo acute myeloid leukemias (5, 46), the t(12;21)(p13;q22) found in 30% of pediatric de novo acute lymphocytic leukemias (24, 42, 61, 62, 66), and the relatively rare t(3;21)(q26;q22) and t(16;21)(q24;q22) found in therapy-related leukemias and myelodysplasias (20, 52, 53). The CBFB gene is disrupted in approximately 15% of acute myeloid leukemias by inv(16)(p13;q22), t(16;16), and del(16)(q22) (39, 67). CBF binds a number of cellular genes transcribed in hematopoietic cells, including genes encoding the T-cell receptor alpha , beta , gamma , and delta  chains (TCRalpha , TCRbeta , TCRgamma , and TCRdelta , respectively), immunoglobulin µ chain, interleukin 3, granulocyte/monocyte colony-stimulating factor, CD3varepsilon , myeloperoxidase, neutrophil elastase, and granzyme B serine protease (8, 16, 19, 21, 28, 30, 51, 59, 60, 76, 84, 87).

The importance of CBF in hematopoietic cells makes it a strong candidate for the factor that contributes to the leukemogenic properties of MLVs in vivo. However, CBF is not the only transcription factor that binds the Moloney and SL3-3 MLV core sites in vitro. Activating protein 3 (AP-3), mammalian C-type retrovirus enhancer factor 1 (MCREF-1), and SL3 core-binding factor (S-CBF) also bind MLV core sites (40, 41, 44, 75), and there may be other core-binding factors not yet identified. To address the question of whether CBF is the relevant core-binding factor for Moloney MLV pathogenesis in vivo, we considered two approaches. One approach is to eliminate or overexpress CBF in mice and determine whether modification of CBF levels affects pathogenesis by Moloney MLV. However, an inherent difficulty with this approach is that hematopoiesis itself may be severely perturbed by anomalous levels of CBF. This is certainly the case when CBFalpha 2 or CBFbeta is eliminated entirely, which severely impairs hematopoiesis, resulting in embryonic lethality (48, 56, 64, 80, 81). Overexpression is also likely to be problematic, as evidenced by the recent discovery that Cbfa1 is a preferential proviral insertion site in lymphomas induced by Moloney MLV in c-myc transgenic mice (72).

An alternative approach, and the tack we chose to follow, is to systematically modify the affinity of CBF for the core site in the Moloney MLV enhancer by altering the nucleotide composition of the site. Our hypothesis was that if CBF is the relevant core-binding factor for Moloney MLV pathogenesis in vivo, we should observe a correlation between the affinity of CBF for its site and the latent period of disease onset, and/or the disease specificity of the virus. To this end, we measured the affinity of CBF for a large panel of naturally occurring and synthetic core sites. We identified core sites whose affinities for CBF span 5 orders of magnitude, engineered those sites into the Moloney MLV genome, and examined their impact on pathogenesis by Moloney MLV. We observed a relationship between CBF affinity and the latent period of disease onset, in that Moloney MLVs with high-affinity CBF binding sites induced leukemia or lymphoma with a shorter latent period than viruses with low-affinity sites. Disease specificity also correlated with the affinity of CBF for its site, supporting a role for CBF in Moloney MLV pathogenesis.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Expression and purification of the CBFalpha 2 Runt domain. A DNA fragment encoding the DNA-binding (Runt) domain from the murine CBFalpha 2 protein (amino acids 41 to 190) (3) was amplified by PCR using the following primers: 5'-CGGAATTCCCATATGGCCAGCAAGCTGAGGAGC-3' (sense) and 5'-CGGGATCCTTACTCGTGCTGGTTCTTCCCGGGCTTGGTCTGATC-3' (antisense). The antisense primer introduces a translational stop codon followed by codons for the amino acids KNQHE immediately 3' to codon 190 of CBFalpha 2. PCR products were digested with NdeI and BamHI, subcloned into the corresponding sites of the pET-3c vector (Novagen, Madison, Wis.), and transformed into the Escherichia coli BL21(DE3)LysS for expression (74). A single colony was grown to an absorbance (A600) of 0.3 to 0.4 in Luria-Bertani (LB) medium containing 100 µg of carbenicillin per ml and 50 µg of chloramphenicol per ml, and a glycerol stock was prepared.

All purification steps were performed at 4°C, unless otherwise noted. A scraping of the frozen bacterial stock was thawed at room temperature, and 1 µl was diluted into 1.0 ml of LB medium. A 1-µl aliquot of this 1:1,000 dilution was used to inoculate 1 liter of LB medium containing 100 µg of carbenicillin per ml and 50 µg of chloramphenicol per ml. The cells were grown for approximately 16 h at 37°C to an absorbance (A600) of 0.3 to 0.4, and expression was induced with 1 mM isopropyl-beta -D-thiogalactopyranoside (IPTG). Cells were harvested between 1 and 3 h postinduction by centrifugation at 4,800 × g. The bacterial pellet was resuspended in an equal weight of lysis buffer (10% sucrose, 50 mM Tris-HCl [pH 7.5], protease inhibitors [1 mM Pefabloc, 1 mM phenylmethylsulfonyl fluoride, 50 µM Calpain inhibitor 1, 1 µg of leupeptin per ml, 1 µg of pepstatin A per ml, 2 µg of aprotinin per ml] [Sigma]). The cells were dropped directly into liquid nitrogen, and frozen cell pellets were stored at -70°C or thawed immediately. Cells were thawed in a room temperature water bath, and ammonium sulfate was added to a final concentration of 0.1 M. The tube was inverted once and incubated on ice for 30 min. Cells were lysed at 37°C for 2.5 min and centrifuged at 40,000 × g for 1 h at 4°C. Soluble protein was collected, dialyzed against 200 volumes of buffer A (150 mM KCl, 20 mM imidazole [pH 7.0], 20 mM beta -mercaptoethanol), and loaded onto a 20-cm3 DEAE-Sephacel column (Pharmacia Biotech, Piscataway, N.J.) equilibrated in buffer A. The flowthrough fraction was collected, dialyzed against 200 volumes of buffer B (50 mM NaCl, 20 mM HEPES [pH 7.5], 20 mM beta -mercaptoethanol, 10% glycerol, 0.05% Triton X-100), and applied to a P-11 phosphocellulose column (1.5 cm3; Whatman), equilibrated in buffer B. The column was developed with a 22-ml linear gradient from 0.05 to 1.0 M NaCl in buffer B. Fractions containing the Runt domain were pooled and exchanged into buffer C (8 mM sodium phosphate [pH 7.5], 50 mM NaCl, 0.05% Triton X-100, 10% glycerol, 10 mM beta -mercaptoethanol), and loaded onto a hydroxylapatite column (1 cm3; HTP, Bio-Rad Laboratories, Richmond, Calif.). The hydroxylapatite column was developed with a 40-ml linear gradient from 8 to 200 mM sodium phosphate in buffer C, and fractions containing the Runt domain were pooled and stored at -70°C. The Runt domain concentration was determined by A280 with the molar extinction coefficient varepsilon  = 11,000 M-1 · cm-1 reported previously (12).

Determination of the active Runt domain concentration. The active Runt domain concentration was determined by titration of known concentrations of DNA onto a fixed concentration of the Runt domain, as described previously (12). The DNA site used in the titrations was derived from the TCRbeta enhancer (GGATATATGTGGTTTGCA). Oligonucleotide concentrations were determined by measuring A260, using extinction coefficients calculated with the Oligo program (National Biosciences, Inc.). One milliliter of a 1:15 dilution of [gamma -32P]ATP (7,000 Ci/mmol; ICN) was used to label 250 pmol of single-stranded oligonucleotide. A portion of the single-stranded DNA was set aside for quantitative purposes (see below), and the remainder of the labeled strand was annealed to an unlabeled complementary strand. All binding reactions and electrophoretic mobility shift assays (EMSA) were performed as described previously (12). Briefly, binding reactions (20 µl of total volume) were performed at 4°C for 20 min in a solution consisting of 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 5 mM dithiothreitol, 0.2 µg of bovine serum albumin per ml, 0.05% Triton X-100, and 4% glycerol. The Runt domain concentration in all reaction mixtures (5 × 10-8 M) was 100-fold above the Kd of the Runt domain for this particular DNA site, and the concentration of DNA was varied. Portions (15 µl) of the binding reaction mixtures were loaded onto a running gel (10% polyacrylamide) at 4°C to separate free DNA from protein-bound DNA. For each DNA concentration, three reaction mixtures were analyzed: (i) one with the Runt domain added, (ii) a control containing the double-stranded DNA probe alone, and (iii) the labeled single-stranded DNA of known concentration. The amount of free DNA in each lane was determined with a PhosphorImager 445SI Scanner (Molecular Dynamics, Sunnyvale, Calif.) and IPLab gel. [Df], the concentration of free double-stranded DNA in lanes containing the Runt domain, and [Dt], the concentration of free double-stranded DNA in the corresponding control lane without added Runt domain, were determined by comparison to the free single-stranded DNA standard of known concentration. The concentration of bound DNA, [PD], was determined from the equation [PD]/[Dt] = 1 - [Df]/[Dt]. Concentrations of active protein were determined from the asymptote when [PD] versus [Dt] was plotted.

Equilibrium dissociation constants. Equilibrium dissociation constants were determined by the method of Jonsen et al. (32), using the binding and EMSA conditions described above. DNA concentrations were at least 10-fold lower than the estimated Kd of the Runt domain for the DNA site, ensuring the total active protein concentration, [Pt], was an accurate estimate of free protein, [P]. The fraction of free DNA, [Df]/[Dt], was the ratio of the free DNA signal analyzed at each protein concentration to the DNA signal in a control lane containing no protein. The fraction of DNA in complex with protein was derived from the equation [PD]/[Df] = 1 - [Df]/[Dt]. All datum points were fit to the rearranged mass action equation, [PD]/[Dt] = 1/(1 + Kd/[P]), using nonlinear least-squares analyses (Kaleidagraph; Synergy Software).

Sequences of the double-stranded binding sites used to measure the equilibrium dissociation constants are listed on the next page.
Moloney MLV 5'-GGATATCTGTGGTAAAGCA-3'
3'-CCTATAGACACCATTTCGT-5'
SL3-3 MLV 5'-GGATATCTGTGGTTAAGCA-3'
3'-CCTATAGACACCAATTCGT-5'
Akv 5'-GGATATCTGTGGTCAAGCA-3'
3'-CCTATAGACACCAGTTCGT-5'
MCF247 5'-GGATATCTGTGGTCGAGCA-3'
3'-CCTATAGACACCAGCTCGT-5'
Rauscher MCF 5'-GGATATCTGCGGTGAGCA-3'
3'-CCTATAGACGCCACTCGT-5'
MX 5'-GGATATCGGTGGTCAAGCA-3'
3'-CCTATAGCCACCAGTTCGT-5'
Soule MLV 5'-GGATATCTGCGGTCAGCA-3'
3'-CCTATAGACGCCAGTCGT-5'
TCRalpha 5'-GGATATATGTGGCTTGCA-3'
3'-CCTATATACACCGAACGT-5'
TCRbeta delta 5'-GGATATATGTGGTTTGCA-3'
3'-CCTATATACACCAAACGT-5'
TCRgamma 5'-GGATATCTGTGGTTTGCA-3'
3'-CCTATAGACACCAAACGT-5'
HA 5'-GGATATTTGCGGTTAGCA-3'
3'-CCTATAAACGCCAATCGT-5'
SAAB 5'-GGATATCTGCGGTTTGCA-3'
3'-CCTATAGACGCCAAACGT-5'
SS4 5'-GGATATCTGCGGAAGGCA-3'
3'-CCTATAGACGCCTTCCGT-5'
SS5 5'-GGATATCTGTGGAAGAGCA-3'
3'-CCTATAGACACCTTCTCGT-5'
Mo(core) 5'-GGATATCTGCCGTAAAGCA-3'
5'-CCTATAGACGGCATTTCGT-5'

Plasmids and mutations. DNA fragments used for subcloning were derived from the plasmids pMoCAT, pMo(CORE)CAT, and pMoDelta RVCAT. pMoCAT contains the wild-type Moloney MLV enhancer linked to the bacterial chloramphenicol acetyltransferase (CAT) gene, and pMo(CORE)CAT is the same plasmid with mutations in both core sites of the Moloney MLV enhancer that reduce CBFalpha 2 binding by 1,000 fold (71; this study). pMoDelta RVCAT lacks the EcoRV-EcoRV fragment within the enhancer direct repeat. From these initial plasmids, four additional vectors were made: pMoRV (Fig. 1) contains the EcoRV-EcoRV enhancer fragment from pMoCAT, subcloned into the EcoRV site of pBluescript SK+ (Stratagene). pMoLUC, pMoDelta RVLUC, and pMo(CORE)LUC contain a Sau3AI-KpnI fragment from the Moloney MLV U3/R region subcloned into the BamHI-KpnI site of the pxp1 vector, a promoterless vector containing the firefly luciferase gene (LUC) (14, 49).


View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1.   Strategy for introducing altered core sites into the Moloney MLV enhancer. (A) Introducing point mutations into the promoter-distal copy of the enhancer direct repeats. White bars represent sequences from the Moloney MLV genome. Black bars represent sequences from the bacterial chloramphenicol acetyltransferase (CAT) gene or the luciferase gene (LUC). Black lines represent bacterial vector DNA sequences. A small gray square represents one copy of the 75-bp direct repeat. The PCR primer locations (arrows) and core site mutations (asterisks) are indicated. The luciferase reporter plasmid (pxp1) is a promoterless vector linked to the firefly luciferase gene (LUC) (14, 49). Abbreviations: B, BamHI; RV, EcoRV; K, KpnI; S, Sau3AI. (B) Introducing mutations into the promoter-proximal copy of the direct repeat. (C) Introducing mutated enhancers into the luciferase reporter vector. Sequences from Sau3AI7910-KpnI8296 of Moloney MLV (85) encompass the 75-bp repeat and extend 30 bp 3' to the viral cap site.

The strategy for introducing core site mutations into the Moloney enhancer is illustrated schematically in Fig. 1. Mutations were made by PCR, using primers with the following sequences (core sites are underlined, and lowercase letters indicate the mutated nucleotides), in conjunction with an antisense primer (LUC) from luciferase coding sequences: Soule (sense), 5'-CAGGATATCTGcGGTcAGCAGTTCC-3'; SL3-3 (sense), 5'-CAGGATATCTGTGGTtAGCAGTTCCT-3'; MX (sense), 5'-CAGGATATCgGTGGTcAGCAGTTCC-3'; SS4 (sense), 5'-CAGGATATCTGcGGaAgGCAGTTCCTG-3'; SS5 (sense), 5'-CAGGATATCTGTGGaAgGCAGTTCCTG-3'; and LUC (antisense), 5'-CCGGGCCTTTCTTTATGT-3'.

All core site sequences were terminated at the 5' and 3' ends of the CBF phosphate contacts defined previously (underlined) (43). Core sequences were fused directly to Moloney MLV flanking sequences in such a way as to maintain the orientation and spacing of other protein binding sites on the Moloney enhancer. Mutations were introduced into each copy of the direct repeat in two separate subcloning steps. First, each sense primer was used with the LUC1 antisense primer and pMoDelta RVLUC as a template in PCRs that amplified from nucleotide 8029 of the Moloney MLV genome to nucleotide 86 of the luciferase gene. The PCR products were digested with EcoRV and KpnI, and isolated fragments were used to replace the corresponding region in pMoDelta RVCAT to create the pMo(*)Delta RVCAT vectors [pMo(Soule)Delta RVCAT, pMo(SL3)Delta RVCAT, pMo(MX)Delta RVCAT, pMo(SS4)Delta RVCAT, and pMo(SS5)Delta RVCAT] (Fig. 1A). Core site mutations were independently introduced into the 75-bp EcoRV-EcoRV fragment of the Moloney enhancer by PCR using pMoRV as a template and the same sense primers in conjunction with an antisense primer that hybridizes to the T7 promoter in the pBluescript SK+ vector. The PCR products were digested with EcoRV and subcloned into the EcoRV site of the pMo(*)Delta RVCAT vectors, generating pMo(*)CAT vectors with identical core site mutations in both copies of the Moloney MLV enhancer direct repeat [pMo(Soule)CAT, pMo(SL3)CAT, pMo(MX)CAT, pMo(SS4)CAT, and pMo(SS5)CAT] (Fig. 1B). Finally, these mutated Moloney enhancers were excised from the pMo(*)CAT plasmids with Sau3A1 and KpnI and transferred into the BamHI-KpnI sites of the firefly luciferase vector (pxp1) to generate pMo(Soule)LUC, pMo(SL3)LUC, pMo(MX)LUC, pMo(SS4)LUC, and pMo(SS5)LUC (Fig. 1C). The correct sequence of all enhancer segments generated by PCR was confirmed.

Substitution of the mutated Moloney MLV enhancers into the infectious Moloney MLV genome was performed as described previously (70).

Cell lines. Cell lines were used in transfection experiments or for the generation of infectious virus as follows. A human mature T-cell line (Jurkat) and a murine pro-T-cell line (2017) were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 U of penicillin per ml, 100 µg of streptomycin per ml, and 2 mM L-glutamine. A murine mature T-cell line, D5H3, was maintained in Dulbecco modified Eagle medium supplemented with 10% FBS, 100 U of penicillin per ml, 100 µg of streptomycin per ml, 2 mM L-glutamine, 0.01 M HEPES (pH 7.9), and 5 mM beta -mercaptoethanol. After transfection, D5H3 cells were transferred into the same medium with 5% FBS and 5% newborn bovine serum. NIH 3T3 cells were maintained in Dulbecco modified Eagle medium with 10% FBS, 2 mM L-glutamine, and antibiotics.

Luciferase assays. Cells were transfected by the DEAE-dextran method (34). Briefly, 107 Jurkat and 2017 cells or 5 × 106 D5H3 cells were transfected with 5 µg of the Mo(*)LUC reporter plasmids and 5 µg of CMVhGH, a plasmid containing cDNA encoding the human growth hormone driven from a cytomegalovirus enhancer (Nichols Institute Diagnostics, San Juan Capistrano, Calif.). Jurkat cells were induced with 1 µg of 1,3-phorbol myristate acetate per ml at 24 h posttransfection. Cells were harvested 48 h posttransfection, washed once with phosphate-buffered saline, and lysed in 160 µl of lysis buffer (1% [vol/vol] Triton X-100, 25 mM glycylglycine [pH 7.8], 15 mM MgSO4, 4 mM EGTA, 1 mM dithiothreitol) by vortexing for 30 s at room temperature. Supernatants were harvested and assayed immediately for luciferase enzyme activity (14, 25). The results were normalized against protein concentration and human growth hormone levels.

Generating infectious viruses. We transfected three independent molecular clones of each mutated viral genome into NIH 3T3 cells as previously described (70). Cells were split 1:10 into duplicate plates 8 to 12 h following transfection, and XC plaque assays were performed directly on one such plate (63). In all cases, XC plaques were present. The remaining plate was maintained for 2 weeks, at which time the culture supernatants were assayed for reverse transcriptase activity (4). Virus was harvested after 2 to 3 weeks, by which time the virus had spread throughout the culture, as determined by XC plaque assay.

Mice, tumor induction, and classification of disease. Newborn (<2-day-old) NFS mice were inoculated intraperitoneally and intrathymically with 0.04 ml of tissue culture-grown virus, representing from 104.3 to 105.3 PFU/mouse. Viruses from two or three independent molecular clones from each enhancer mutation were injected. Animals were monitored regularly for overt signs of disease. Diagnosis of erythroleukemia, lymphoma, or myelogenous leukemia was based on gross pathology and histology, as described previously (10). Briefly, diagnosis of lymphoblastic lymphoma was based on gross findings of enlarged thymus, lymph nodes, or both, and histological observation of diffuse infiltration with lymphoblasts of splenic white pulp, thymus, and lymph nodes, and often liver. Spleens were normally but not invariably enlarged. Spleen DNA from cases of lymphoblastic leukemia without thymic enlargement was analyzed for TCRbeta and immunoglobulin heavy-chain (IgH) rearrangements by Southern blotting (26, 29, 35). Mice with erythroleukemia showed severe anemia and had enlarged spleens with erythroblast infiltration of expanded red pulp and enlarged livers with blast infiltration within sinusoids, the thymus was never enlarged, and lymph nodes were normal or showed enlarged germinal centers.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Expression and purification of the Runt domain. We used the isolated DNA-binding Runt domain from the murine CBFalpha 2 protein to measure equilibrium dissociation constants for different core sites. Although the Runt domain's affinity for any given DNA site may differ from that of the full-length CBFalpha 2-CBFbeta heterodimer, its relative affinities for different core sites should be comparable to those of the full-length proteins. We expressed a fragment spanning amino acids 41 to 190 of CBFalpha 2 that contains the Runt domain, plus additional sequences at the N and C termini of the Runt homology region that we found improved both expression in bacteria and DNA binding (unpublished results). We also added the pentapeptide KNQHE to the C terminus of the Runt domain that was shown to decrease degradation of the P22 Arc repressor in bacteria (7, 45, 57, 58). We purified the Runt domain from the soluble fraction of a bacterial cell lysate by sequential chromatography on DEAE-Sephacel, P11 phosphocellulose, and hydroxylapatite, as described in Materials and Methods, and summarized in Fig. 2 and Table 1. The overall yield of the protein was 20%, and the estimated purity was >95%.


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 2.   Expression and purification of the CBFalpha 2 Runt domain. (A) Schematic diagram of full-length CBFalpha 2(451) (3) with the boundaries of the expressed Runt domain shown below. Black rectangles indicate the 128-amino-acid region of homology shared by the Drosophila and mammalian CBFalpha proteins. The t(8;21)(q22;q22), t(3;21)(q26;q22), t(16;21)(q24;q22), and t(12;21)(p13;q22) breakpoint locations are indicated by arrows. The KNQHE C-terminal tag is indicated by the gray bar. (B) Purification of the CBFalpha 2 Runt domain. (Left) Coomassie brilliant blue-stained sodium dodecyl sulfate-polyacrylamide gel with active fractions from each step of the purification. Lanes: M, molecular markers (in kilodaltons); 1, soluble supernatant from crude bacterial cell lysate; 2, DEAE-Sephacel flowthrough fraction; 3, phosphocellulose eluate; 4, hydroxylapatite eluate. The arrow indicates the location of the CBFalpha 2 Runt domain fragment. (Right) Silver-stained sodium dodecyl sulfate-polyacrylamide gel of representative active fractions (66 to 94) from the hydroxylapatite column. Lane L (for load) contains the phosphocellulose eluate. (C) Activity of the purified Runt domain quantified by DNA titration in an EMSA. Concentrations (molar) of protein-DNA complex [PD] versus total input DNA [Dt] are plotted.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Purification of the CBFalpha 2 Runt domaina

We determined the concentration of Runt domain active for DNA binding by titrating DNA of known concentration onto protein of unknown active concentration until saturation of protein with DNA was achieved (Fig. 2C). The percent active protein was approximated from the asymptote of the curve that resulted from plotting the total concentration of DNA versus the concentration of protein-DNA complex. The purified Runt domain was estimated to be 80 to 100% active compared to the total protein concentration.

Equilibrium dissociation constants of the Runt domain for various core sites. We measured the affinity of the Runt domain for different core sites (Table 2) by equilibrium binding analysis, using the EMSA. The core sites tested were derived from MLV enhancers (23, 73), the TCRalpha , -beta , -gamma , and -delta enhancers (21, 30, 59, 60), and five synthetic sites. The five synthetic sites include the high-affinity (HA) site identified by Thornell et al. (77), a site identified by selected and amplified binding analysis (SAAB) (43), a site containing an A at position 7 known to decrease CBF binding (SS4) (33), a site similar to SS4 that incorporates a Cright-arrowT transition at the fourth position (SS5), and the original mutant core site, Mo(core), that altered disease specificity of Moloney MLV from T-cell leukemia to erythroleukemia (70). All core sites were flanked at the 5' and 3' ends with sequences derived from the Moloney MLV enhancer. Affinities of the CBFalpha 2 Runt domain for different core sites were determined by titrating purified Runt domain of known active concentration onto DNA at a concentration at least 10-fold lower than the Kd of the Runt domain for that site. The Runt domain-DNA complex was separated from free DNA by EMSA, and the ratio of Runt domain (CBFalpha )-DNA complex to total DNA (Dt) was then plotted against the active concentration of the Runt domain to obtain a Kd value (Fig. 3 and Table 3).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Core sites used for equilibrium binding analysisa


View larger version (42K):
[in this window]
[in a new window]
  		FIG. 3.   Equilibrium dissociation constants (Kd) for the CBFalpha 2 Runt domain on representative core sites. EMSAs were performed in the presence of increasing concentrations of the Runt domain indicated on the x axis, plotted against the percent Runt domain (CBFalpha )-DNA complex formation on the y axis. For each core site, data from at least two experiments are presented as points plotted on a single graph and fit to a single curve to obtain the Kd.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Summary of equilibrium binding constants

The equilibrium dissociation constants of the CBFalpha 2 Runt domain for the core sites tested spanned 5 orders of magnitude. We organized the sites into six groups (Table 3). Group I contains the highest-affinity sites and includes the site identified by selected and amplified binding analysis (CTGCGGTTT) (43), and the original high-affinity site identified by Thornell et al. (TTGCGGTTA) (77). Group I also includes the core site from the Soule MLV enhancer (CTGCGGTCA). All three high-affinity sites contain a C in the fourth position (underlined in each site). Values obtained with the Soule MLV core site fluctuated from one experiment to the next for unknown reasons. Thus, data from six separate experiments were plotted on one graph to obtain the best possible Kd estimate for the Soule site (Fig. 3).

The core sites in the Moloney, SL3-3, and Akv enhancers fell into the second highest affinity group (Table 3, group II). The group II sites had, on average, a 10-fold-lower affinity for the Runt domain than the group I sites. All of the group II sites, except for the Rauscher MLV site, possess a T in the fourth position, as opposed to the C found in the highest-affinity group I sites. The Runt domain affinities for the Moloney and SL3-3 MLV core sites were equivalent. The Runt domain affinity for the Akv core site was less than twofold lower than for the SL3-3 MLV site, consistent with previously published data (86).

Group III sites include the TCRalpha and -beta core sites, and the site found in the endogenous polytropic MX33 and MX27 viruses (MX). Both the TCRalpha and -beta sites differ from those in groups I and II at position 1 (A versus C), a substitution previously shown by Thornell et al. (77) to decrease CBF binding. MX is unique among sites with a G at position 2, which was also previously shown to decrease CBF binding (77).

Group IV consists of the SS4 site, which has the favorable C shared by the highest-affinity core sites in group I (CTGCGGAAG), but an A at position 7 where T is found in most other sites (CTGCGGAAG). We created an even lower affinity site by replacing the C in the fourth position of SS4 with a T to generate SS5 (CTGTGGAAG). Group V consists of the SS5 site. The lowest-affinity site, Mo(core), was the sequence originally introduced into the Moloney MLV enhancer by Speck et al. (70), which significantly altered the disease specificity of Moloney MLV from T-cell leukemia to erythroleukemia. The 2-bp mutation in this site (CTGCCGAAG) presumably disrupts contacts made by CBF to the purine base in the fifth position (82). Weak binding precluded measurement of an accurate Kd value for this core site, and therefore only an approximate Kd is reported. Group VI consists of the Mo(core) site.

The Kd values obtained for the HA and SL3 sites are lower than those reported elsewhere from our laboratory (12, 13). We believe this is due to the presence of the C-terminal KNQHE tag in this particular Runt domain fragment, which may somehow stabilize the overall fold of the isolated domain.

Relationship of CBF affinity and transcriptional activity. To determine whether there is a correlation between the affinity of CBF for different core sites and transcriptional activity in T cells, core sites with a range of affinities for the Runt domain were engineered into the Moloney MLV enhancer, and transcriptional activity was measured in several T-cell lines. One core site from each of groups I to VI was analyzed. Sites were chosen to reduce the possibility of interfering with protein assembly on adjacent sites in the Moloney MLV enhancer. For example, the Soule MLV site (CTGCGGTCA) was chosen to represent group I, since the HA site (TTGCGTTA) has a substitution at position 1 relative to Moloney MLV (CTGTGGTAA) that could theoretically perturb proteins binding to sequences immediately flanking the core site. The Soule MLV site was also deemed preferable to the selected and amplified binding site (SAAB) because it shares an A with Moloney MLV at position 9. The core sites engineered into the Moloney MLV enhancer in order of affinity from highest to lowest are as follows: Soule > SL3-3 > MX > SS4 > SS5 > Mo(core). PCR mutagenesis was used to introduce the selected core sites into both copies of the Moloney MLV direct repeat, which in turn was subcloned into a reporter plasmid containing the firefly luciferase gene (see Material and Methods and Fig. 1). Transcription was analyzed in three T-cell lines; Jurkat, 2017, and D5H3 (Fig. 4). The pattern of transcriptional activity from cell line to cell line was very similar. In general, Moloney MLV enhancers containing the higher-affinity sites (groups I and II) displayed a higher level of transcriptional activity than Moloney MLV enhancers with lower-affinity sites (groups III and VI), but a strict correlation between core site affinity and transcriptional activity was not observed. Specifically, there was not a linear decrease in transcriptional activity that matched the progressive decrease in core site affinity for CBF. For example, the enhancer with the highest-affinity core site (Soule MLV, Kd = 5.7 × 10-12 M), displayed only half the transcriptional activity in all three T-cell lines compared to the enhancer containing the next lowest affinity core site, SL3-3 (Kd = 2.4 × 10-11 M). An even more dramatic deviation was observed with the MX core site (Kd = 1.7 × 10-10 M) from group III, which conferred almost no transcriptional activity in any T-cell line tested. The level of transcription driven by the MX core site was equal to or below that conferred by the lowest-affinity site, Mo(core), despite the fact that the Runt domain affinity for the MX site was approximately 200-fold higher than for Mo(core) (Kd >=  4.0 × 10-8 M).


View larger version (26K):
[in this window]
[in a new window]
  		FIG. 4.   Effects of different core sites on transcription driven by the Moloney MLV enhancer in T cells. (A) Sequence represents the promoter-distal copy of the direct repeat (dr). Core mutations were introduced into both copies of the direct repeat. Binding sites for nuclear factors are boxed. Bases identical to those in the Moloney MLV enhancer are indicated by dots, and capital letters indicate base pair substitutions. (B) Transcriptional activity in Jurkat cells, induced with 1,3-phorbol myristate acetate (1 µg/ml) 24 h posttransfection, 2017 cells, and D5H3 cells. Core sites are arranged in order of decreasing affinity for the Runt domain (from left to right). The absolute luciferase activity was normalized to the protein concentration in each sample (relative luciferase units [RLU] on the y axis. Datum points represent the means of three experiments performed on the same day. Error bars represent the standard deviations for the three experiments.

Pathogenesis of Moloney MLVs containing altered core sites. We introduced core sites from groups I to VI into the Moloney MLV genome, generated infectious viruses, and analyzed the pathogenicity of these viruses in newborn NFS mice. Virus stocks generated from two or three independent molecular clones for each enhancer mutation were analyzed (Fig. 5 and Table 4). All viruses were leukemogenic, but their pathogenic properties varied. The latent period of disease onset appeared to inversely correlate with the transcriptional activity conferred by these core sites in T cells. The viruses could be divided into two groups with respect to latent period (Fig. 5). Viruses containing high-affinity core sites (Mo:Soule and Mo:SL3-3) that conferred relatively high transcriptional activity in T cells induced disease with significantly shorter latent periods than viruses containing low-affinity sites (Mo:MX, Mo:SS4, Mo:SS5, and Mo:core). The differences in latent periods among the three high-affinity core site viruses (Moloney, Mo:Soule, and Mo:SL3-3) or among the viruses containing low-affinity sites (Mo:MX, Mo:SS4, Mo:SS5, and Mo:core) were not statistically significant by analysis of variance. By this analysis, however, there was a statistically significant difference between the latent periods of disease onset associated with the higher-affinity core site viruses (Moloney, Mo:Soule, and Mo:SL3-3) and the latencies associated with the lower-affinity core site viruses (Mo:MX, Mo:SS4, Mo:SS5, and Mo:core).


View larger version (14K):
[in this window]
[in a new window]
  		FIG. 5.   Leukemia induction in NFS mice. Leukemia induction as a function of time, following injection of newborn NFS mice with the wild-type Moloney virus and viruses containing altered core sites.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 4.   Latent period of disease induction and types of leukemia and lymphoma cause by wild-type and mutant Moloney viruses

Table 4 shows the frequency of each type of hematopoietic neoplasm induced by viruses containing mutations in the enhancer sequence. Moloney viruses containing cores sites from groups I and II (including wild-type Moloney MLV) induced exclusively T-cell lymphomas. Moloney viruses containing the lower-affinity MX core site (group III) induced primarily lymphoblastic lymphomas (12 of 17 neoplasms [71%]). In three additional cases, splenomegaly and lymphadenopathy were predominant features but molecular analysis of the TCRbeta and IgH loci detected no rearrangements. Histologically these tumors were poorly differentiated, composed of lymphoblast-like cells with abundant cytoplasm, vesicular chromatin pattern, and prominent nucleoli, with undifferentiated, possibly myeloid blasts in peripheral smears. These cases could represent very early B-cell lymphomas that have not rearranged their IgH alleles, as may be the case in prenatal pre-B-cell lymphomas in Eµ-myc and Eµ-pim-1 double transgenic mice (79), or they could be lymphomas of lymphoid precursors or stem cells. Further testing will be required to classify these cases definitively.

The Mo:SS4 virus induced two cases of myelogenous leukemia and two of lymphoblastic leukemia (T- or B-cell origin not molecularly determined). The small numbers of mice infected with Mo:SS4 precludes a clear definition of its pathogenicity. Viruses in the groups with the lowest-affinity sites groups V and VI (Mo:SS5 and Mo:core) induce no myeloid tumors, but a significant percentage of erythroleukemias. Therefore, T-cell disease specificity appeared to correlate with core site affinity, in that viruses with relatively low-affinity core sites do not maintain the exquisite T-cell disease specificity of Moloney MLV and instead induce a variety of leukemias.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

CBF is one of many proteins that bind MLV enhancers and one of several transcription factors that bind the core site. Here we show that the affinity of CBF for its DNA-binding site in Moloney MLV correlates with the latent period of disease onset and disease specificity of the virus. Altered Moloney viruses that contain high-affinity CBF binding sites induce predominantly thymic lymphoblastic lymphomas, whereas viruses with lower-affinity CBF binding sites lose the exquisite T-cell disease specificity of Moloney MLV. The results suggest that CBF, which was identified as a candidate host cell transcription factor responsible for the T-cell disease specificity of Moloney MLV (82), may in fact be contributing to the T-cell disease specificity of this virus in vivo. It is also formally possible that we inadvertently created high-affinity binding sites for proteins expressed in hematopoietic cells other than T cells upon introducing low-affinity CBF binding sites into the Moloney MLV enhancer and that this caused alterations in disease specificity.

Although the affinity of CBF for its site appears to correlate with the latent period of disease onset and T-cell disease specificity, it does not do so in a linear fashion. Rather, there appears to be an affinity threshold for inducing T-cell lymphoma following a rapid latent period. The Moloney, Mo:Soule, and Mo:SL3-3 MLVs contain core sites above this affinity threshold and induce exclusively T-cell lymphomas following a short latent period. Mo:MX, Mo:SS4, Mo:SS5, and Mo:core contain core sites below the affinity threshold and induce a mixture of T- and B-cell lymphomas, myeloid leukemias, and erythroleukemias following a longer latent period.

Although there was a rough correlation between CBF affinity and transcriptional activity in T cells, two core sites deviated from this pattern for reasons we do not fully understand. The Soule MLV core site, which is in the group of high-affinity sites (group I), and bound CBF with a sevenfold-higher affinity than the SL3-3 core site, conferred lower levels of transcription to the Moloney MLV enhancer than the SL3-3 site. The difficulty we experienced in measuring a dissociation constant for the Soule MLV site may have caused us to underestimate the Kd, although in no experiments did we measure a Kd for the Soule core site that was higher than that for SL3-3. Another possible explanation for this discrepancy is that the mutation we introduced in the Moloney enhancer to generate the Soule MLV site may have altered binding of other proteins to the enhancer. In this regard, we note that the C at position 8 of the Soule site is shared by the Akv virus. In other studies, it has been demonstrated that the C at position 8 in Akv, when used to replace the T at that same position in the SL3-3 virus, reduces transcription from the SL3-3 enhancer in T cells and attenuates pathogenesis (6, 47). Similarly, this alteration in the Moloney MLV enhancer, while not significantly affecting CBF affinity (compare the Moloney MLV and Akv sites in Table 3), may nevertheless be responsible for reducing transcriptional activity in T cells. Our experiments support the hypothesis put forth by Zaiman et al. (86), that the T-versus-C difference in the SL3-3 and Akv core sites is most likely influencing transcription and pathogenesis through some protein other than (or in addition to) CBF, since the affinities of CBF for the SL3-3 and Akv sites are very similar.

The other unexpected result was that obtained with the endogenous polytropic and modified polytropic MX viruses. When this core site was introduced into the Moloney MLV enhancer, it dramatically reduced transcription in T cells, as much as or even more than the Mo(core) mutation that essentially eliminates CBF binding. Again, the data suggest that the sequence alteration impacted on some other protein binding to the enhancer in T cells. The Ets proteins, for example, bind the adjacent LVb site 5' to the core site. However, preliminary data (not shown) indicated that Ets-1 binding was not appreciably affected by the MX mutation. The MX site also has a C at position 7, similar to Soule and Akv. Pathogenicity was affected, in that there was increased heterogeneity in tumor phenotype and latency was prolonged.

We note that most MLVs contain relatively high-affinity CBF binding sites (groups I and II). Only the endogenous polytropic and modified polytropic viruses (MX27 and MX33) contain low-affinity CBF sites. The endogenous polytropic viruses are replication defective and serve as env donors for recombinant MCF viruses, but the enhancers from these viruses are not found in infectious MLVs (73). Thus, it appears that CBF has the potential to act on most MLV enhancers in vivo.

The expression pattern of Cbfa2, which encodes the CBFalpha subunit originally purified from thymus tissue (82), may shed some light on why the lowest-affinity core sites in the Moloney MLV enhancer [SS5 and Mo(core)] tend to shift disease specificity toward erythroleukemia. Cbfa2 is highly expressed in c-kit+ CD34+ fetal liver hematopoietic stem cells and in bone marrow (11, 15, 50). Expression remains high in the thymus and in some (if not all) myeloid lineages but appears to be rapidly downregulated in both the primitive and definitive erythroid lineages (11, 50, 65, 68). Thus, CBF may not be important for Moloney MLV replication in cells of the erythroid lineage. Low-affinity core sites may selectively impair transcription of the Moloney MLV genome in lymphocytes and in myeloid lineages, but not in erythroid progenitors, hence shifting the distribution of leukemias toward the erythroid lineage.


    ACKNOWLEDGMENTS

We thank Barbara Graves for advice in measuring dissociation constants and the members of Bill Green's laboratory for help in generating infectious viruses. We also thank Torgny Fredrickson for histopathology consultation, Sandy Morse and Sisir Chattopadhyay for critical comments, and Zohreh Nagashfar for technical assistance. We also gratefully acknowledge Sisir Chattopadhyay for providing DNA probes.

This work was supported in part by Public Health Service grants R01 CA58343 and CA75611 (awarded to N.A.S.) and by contract N01-AI-45203 at MA Bioservices, Inc., Rockville, Md. A.F.L. was supported by a Cancer Biology Training Grant CA09658. W.R.G. is supported by CA 69525. N.A.S. is a Leukemia Society of American Scholar.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755. Phone: (603) 650-1159. Fax: (603) 650-1128. E-mail: Nancy.A.Speck{at}dartmouth.edu.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Amtoft, H. W., A. B. Sorensen, C. Bareil, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants. J. Virol. 71:5080-5087[Abstract].
2. Bae, S.-C., E. Takahashi, Y. W. Zhang, E. Ogawa, K. Shigesada, Y. Namba, M. Satake, and Y. Ito. 1995. Cloning, mapping and expression of PEBP2alpha C, a third gene encoding the mammalian Runt domain. Gene 159:245-248[Medline].
3. Bae, S. C., Y. Yamaguchi-Iwai, E. Ogawa, M. Maruyama, M. Inuzuka, H. Kagoshima, K. Shigesada, M. Satake, and Y. Ito. 1993. Isolation of PEBP2alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 8:809-814[Medline].
4. Baltimore, D. 1970. RNA-dependent DNA polymerase in virions of RNA tumor viruses. Nature 226:1209-1211[Medline].
5. Bitter, M. A., M. M. LeBeau, J. D. Rowley, R. A. Larson, H. M. Golomb, and J. W. Vardiman. 1987. Association between morphology, karyotype, and clinical features in myeloid leukemias. Human Pathol. 18:211-225[Medline].
6. Boral, A. L., S. A. Okenquist, and J. Lenz. 1989. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element. J. Virol. 63:76-84[Abstract/Free Full Text].
7. Bowie, J. U., and R. T. Sauer. 1989. Identification of C-terminal extensions that protect proteins from intracellular proteolysis. J. Biol. Chem. 264:7596-7602[Abstract/Free Full Text].
8. Cameron, S., D. S. Taylor, E. C. TePas, N. A. Speck, and B. Mathet-Prevot. 1994. Identification of a critical regulatory site in the human interleukin-3 promoter by in vivo footprinting. Blood 83:2851-2859[Abstract/Free Full Text].
9. Chatis, P. A., C. A. Holland, J. W. Hartley, W. P. Rowe, and N. Hopkins. 1983. Role for the 3' end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses. Proc. Natl. Acad. Sci. USA 80:4408-4411[Abstract/Free Full Text].
10. Chatis, P. A., C. A. Holland, J. E. Silver, T. N. Fredrickson, N. Hopkins, and J. W. Hartley. 1984. A 3' end fragment encompassing the transcriptional enhancer of nondefective Friend virus confers erythroleukemogenicity on Moloney murine leukemia virus. J. Virol. 52:248-259[Abstract/Free Full Text].
11. Corsetti, M. T., and F. Calabi. 1997. Lineage- and stage-specific expression of Runt box polypeptides in primitive and definitive hematopoiesis. Blood 89:2359-2368[Abstract/Free Full Text].
12. Crute, B. E., A. F. Lewis, Z. Wu, J. H. Bushweller, and N. A. Speck. 1996. Biochemical and biophysical properties of the CBFalpha 2 (AML1) DNA-binding domain. J. Biol. Chem. 271:26251-26260[Abstract/Free Full Text].
13. Crute, B. E., Y.-Y. Tang, X. Huang, J. J. Kelley III, K. L. Hartman, T. Laue, N. A. Speck, and J. H. Bushweller. Biophysical characterization of interactions between the core binding factor alpha  and beta  subunits and DNA. Submitted for publication.
14. de Wet, J. R., K. V. Wood, M. DeLuca, D. R. Helinski, and S. Subramani. 1987. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7:725-737[Abstract/Free Full Text].
15. Erickson, P. F., G. Dessev, R. S. Lasher, G. Philips, M. Robinson, and H. A. Drabkin. 1996. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 88:1813-1823[Abstract/Free Full Text].
16. Erman, B., M. Cortes, B. S. Nikolajczyk, N. A. Speck, and R. Sen. 1998. ETS-core binding factor: a common composite motif in antigen receptor gene enhancers. Mol. Cell. Biol. 18:1322-1330[Abstract/Free Full Text].
17. Ethelberg, S., B. Hallberg, J. Lovmand, J. Schmidt, A. Luz, T. Grundstrom, and F. S. Pedersen. 1997. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site. J. Virol. 71:1196-1206[Abstract].
18. Ethelberg, S., J. Lovmand, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo. J. Virol. 71:7273-7280[Abstract].
19. Frank, R., J. Zhang, H. Uchida, S. Meyers, S. W. Hiebert, and S. D. Nimer. 1995. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11:2667-2674[Medline].
20. Gamou, T., E. Kitamura, F. Hosoda, K. Shimizu, K. Shinohara, Y. Hayashi, T. Nagese, Y. Yokoyama, and M. Ohki. 1998. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91:4028-4037[Abstract/Free Full Text].
21. Giese, K., C. Kingsley, J. R. Kirshner, and R. Grosschedl. 1995. Assembly and function of a TCRalpha enhancer complex is dependent on LEF-1-induced DNA binding and multiple protein-protein interactions. Genes Dev. 9:995-1008[Abstract/Free Full Text].
22. Golemis, E., Y. Li, T. N. Fredrickson, J. W. Hartley, and N. Hopkins. 1989. Distinct segments in the enhancer region collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses. J. Virol. 63:328-337[Abstract/Free Full Text].
23. Golemis, E., N. A. Speck, and N. Hopkins. 1990. Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J. Virol. 64:534-542[Abstract/Free Full Text].
24. Golub, T. R., G. F. Barker, S. K. Bohlander, S. Hiebert, D. C. Ward, P. Bray-Ward, E. Morgan, S. C. Raimondi, J. D. Rowley, and D. G. Gilliland. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 92:4917-4921[Abstract/Free Full Text].
25. Gould, S. J., and S. Subramani. 1989. Firefly luciferase as a tool in molecular and cell biology, p. 9.6.10-9.6.14. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates and Wiley-Interscience, New York, N.Y.
26. Gross-Belland, M., P. Oudet, and P. Chambon. 1973. Isolation of high molecular weight DNA from mammalian cells. Eur. J. Biochem. 36:32-37[Medline].
27. Hallberg, B., J. Schmidt, A. Luz, F. S. Pedersen, and T. Grundstrom. 1991. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J. Virol. 65:4177-4181[Abstract/Free Full Text].
28. Hallberg, B., A. Thornell, M. Holm, and T. Grundstrom. 1992. SEF1 binding is important for T cell specific enhancers of genes for T cell receptor-CD3 subunits. Nucleic Acids Res. 20:6495-6499[Abstract/Free Full Text].
29. Hedrick, S. M., R. N. Germain, M. Bevan, M. Dorf, I. Engel, P. Fink, N. Gascoigne, E. Heber-Katz, J. Kapp, Y. Kaufmann, J. Kaye, F. Melchers, C. Pierce, R. Schwartz, C. Sorenson, M. Taniguchi, and M. M. Davis. 1985. Rearrangement and transcription of a T-cell receptor B-chain gene in different T cell subsets. Proc. Natl. Acad. Sci. USA 82:531-535[Abstract/Free Full Text].
30. Hsiang, Y. H., D. Spencer, S. Wang, N. A. Speck, and D. H. Raulet. 1993. The role of viral "core" motif-related sequences in regulating T cell receptor gamma  and delta  gene expression. J. Immunol. 150:3905-3916[Abstract].
31. Ishimoto, A., M. Takimoto, A. Adachi, M. Kakuyama, S. Kato, K. Kakimi, K. Fukuoka, T. Ogiu, and M. Matsuyama. 1987. Sequences responsible for erythroid and lymphoid leukemia in the long terminal repeats of Friend-mink cell focus-forming and Moloney murine leukemia viruses. J. Virol. 61:1861-1866[Abstract/Free Full Text].
32. Jonsen, M. D., J. M. Petersen, Q.-P. Xu, and B. J. Graves. 1996. Characterization of cooperative function of inhibitory sequences in Ets-1. Mol. Cell. Biol. 16:2065-2073[Abstract].
33. Kamachi, Y., E. Ogawa, M. Asano, S. Ishida, Y. Murakami, M. Satake, Y. Ito, and K. Shigesada. 1990. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J. Virol. 64:4808-4819[Abstract/Free Full Text].
34. Kingston, R. E. 1989. Transfection of DNA into eukaryotic cells, p. 9.1.1-9.1.3. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates and Wiley-Interscience, New York, N.Y.
35. Lang, R. B., L. W. Stanton, and K. B. Marcu. 1982. On immunoglobulin heavy chain switching: two gamma 2b genes are rearranged via switch sequences in MPC-11 cells but only one is expressed. Nucleic Acids Res. 10:611-630[Abstract/Free Full Text].
36. Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. E. Perkins, and W. A. Haseltine. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature (London) 308:467-470[Medline].
37. Levanon, D., V. Negreanu, Y. Bernstein, I. Bar-Am, L. Avivi, and Y. Groner. 1994. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 23:425-432[Medline].
38. Li, Y., E. Golemis, J. W. Hartley, and N. Hopkins. 1987. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J. Virol. 61:696-700.
39. Liu, P., S. A. Tarle, A. Hajra, D. F. Claxton, P. Marlton, M. Freedman, M. J. Siciliano, and F. S. Collins. 1993. Fusion between transcription factor CBFbeta /PEBP2beta and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044[Abstract/Free Full Text].
40. Losardo, J. E., A. L. Boral, and J. Lenz. 1990. Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity. J. Virol. 64:1756-1763[Abstract/Free Full Text].
41. Manley, N. R., M. A. O'Connell, P. A. Sharp, and N. Hopkins. 1989. Nuclear factors that bind to the enhancer region of nondefective Friend murine leukemia virus. J. Virol. 63:4210-4223[Abstract/Free Full Text].
42. McLean, T. W., S. Ringold, D. Neuberg, K. Stegmaier, R. Tantravahi, J. Ritz, H. P. Koeffler, S. Takeuchi, J. W. Janssen, T. Seriu, C. R. Bartram, S. E. Sallan, D. G. Gilliland, and T. R. Golub. 1996. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 88:4252-4258[Abstract/Free Full Text].
43. Melnikova, I., B. E. Crute, S. Wang, and N. A. Speck. 1993. Sequence specificity of the core-binding factor. J. Virol. 67:2408-2411[Abstract/Free Full Text].
44. Mercurio, F., and M. Karin. 1989. Transcription factors AP-3 and AP-2 interact with the SV40 enhancer in a mutually exclusive manner. EMBO J. 8:1455-1460[Medline].
45. Milla, M. E., B. M. Brown, and R. T. Sauer. 1993. P22 arc repressor: enhanced expression of unstable mutants by addition of polar C-terminal sequences. Protein Sci. 2:2198-2205[Abstract].
46. Miyoshi, H., K. Shimizu, T. Kozu, N. Maseki, Y. Kaneko, and M. Ohki. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88:10431-10434[Abstract/Free Full Text].
47. Morrison, H. L., B. Soni, and J. Lenz. 1995. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J. Virol. 69:446-455[Abstract].
48. Niki, M., H. Okada, H. Takano, J. Kuno, K. Tani, H. Hibino, S. Asano, Y. Ito, M. Satake, and T. Noda. 1997. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc. Natl. Acad. Sci. USA 94:5697-5702[Abstract/Free Full Text].
49. Nordeen, S. K. 1988. Luciferase reporter gene vectors for analysis of promoters and enhancers. BioTechniques 6:454-457[Medline].
50. North, T. E., T.-L. Gu, T. Stacy, Q. Wang, L. Howard, M. Binder, M. Marín-Padilla, and N. A. Speck. Cbfa2 is required for the formation of intraaortic hematopoietic clusters. Development, in press.
51. Nuchprayoon, I., S. Meyers, L. M. Scott, J. Suzow, S. Hieb